NO20060210L - Forbindelser med inhiberende aktivitet pa fosfatidylinositol-3-kinase og fremgangsmate for anvendelse av slike - Google Patents

Forbindelser med inhiberende aktivitet pa fosfatidylinositol-3-kinase og fremgangsmate for anvendelse av slike

Info

Publication number
NO20060210L
NO20060210L NO20060210A NO20060210A NO20060210L NO 20060210 L NO20060210 L NO 20060210L NO 20060210 A NO20060210 A NO 20060210A NO 20060210 A NO20060210 A NO 20060210A NO 20060210 L NO20060210 L NO 20060210L
Authority
NO
Norway
Prior art keywords
methods
compounds
phosphatidylinositol
kinase
inhibitory activity
Prior art date
Application number
NO20060210A
Other languages
English (en)
Inventor
Beth E Dress
Leena Chakravarty
Glenn D Prestwich
Gyorgy Dorman
Mariann Kavecz
Andreas Lukacs
Laszlo Urge
Ference Darvas
Piotr W Rzepecki
Colin Ferguson
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NO20060210L publication Critical patent/NO20060210L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)

Abstract

Forbindelser inhibert med fosfatidylinositol 3-kinase (PI 3-K)-aktiviteter og fremgangmåter med fremstilling og anvendelser derav i behandling av sykdommer er oppdaget. Forbindelser inhibert med PI 3-K-aktivitet og fremgangsmåter med fremstilling ved bruk av PI 3-K-inhibitoriske forbindelser for å inhibere kreftcellevekst eller for å behandle forstyrrelser av immunitet og inflammasjon, hvori PI 3-K spiller en rolle i leukosyttfunksjonen er også forutsatt.
NO20060210A 2003-06-13 2006-01-13 Forbindelser med inhiberende aktivitet pa fosfatidylinositol-3-kinase og fremgangsmate for anvendelse av slike NO20060210L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47822103P 2003-06-13 2003-06-13
PCT/US2004/018752 WO2005016245A2 (en) 2003-06-13 2004-06-14 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20060210L true NO20060210L (no) 2006-03-01

Family

ID=34193025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060210A NO20060210L (no) 2003-06-13 2006-01-13 Forbindelser med inhiberende aktivitet pa fosfatidylinositol-3-kinase og fremgangsmate for anvendelse av slike

Country Status (13)

Country Link
US (1) US20070010548A1 (no)
EP (1) EP1648463A2 (no)
JP (1) JP2007500249A (no)
KR (1) KR20060070486A (no)
CN (1) CN1823067A (no)
AU (1) AU2004264834A1 (no)
BR (1) BRPI0411364A (no)
CA (1) CA2528938A1 (no)
IL (1) IL172426A0 (no)
NO (1) NO20060210L (no)
RU (1) RU2006100484A (no)
WO (1) WO2005016245A2 (no)
ZA (1) ZA200509961B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1746097T3 (da) * 2005-07-20 2010-05-25 Aventis Pharma Sa 1,4-dihydropyridin-kondenserede heterocykliske ringe, fremgangsmåde til fremstilling af disse, anvendelse og sammensætninger, der indeholder dem
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
EP2952186A1 (en) * 2007-03-26 2015-12-09 University Of Southern California Compositions for inducing apoptosis by stimulating ER stress
WO2009147187A1 (en) * 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
EP2280959B1 (en) 2008-06-05 2012-04-04 Glaxo Group Limited 4-amino-indazoles
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
WO2009147189A1 (en) * 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
CA2731909A1 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
PL2899191T3 (pl) 2009-04-30 2018-01-31 Glaxo Group Ltd Indazole podstawione oksazolem jako inhibitory kinazy PI3
FR2945535B1 (fr) * 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
US20120238559A1 (en) * 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
WO2011067365A1 (en) * 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2909204B1 (en) * 2012-10-12 2018-12-05 The Broad Institute, Inc. Gsk3 inhibitors and methods of use thereof
RU2020108454A (ru) 2017-07-31 2021-09-02 Дзе Трастиз Оф Коламбия Юниверсити Ин Дзе Сити Оф Нью Йорк Соединения, композиции и способы лечения t-клеточного острого лимфобластного лейкоза
AR129281A1 (es) * 2022-05-10 2024-08-07 Relay Therapeutics Inc INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS
CN115353515A (zh) * 2022-09-08 2022-11-18 南京苏亦欣医药科技有限公司 一种医药中间体吡唑并喹啉酮衍生物的制备方法及催化剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935222A (en) * 1975-04-16 1976-01-27 E. R. Squibb & Sons, Inc. 1,4,5,7-Tetrahydropyrazolo[3,4-b]pyridin-6-ones
GR79111B (no) * 1982-12-20 1984-10-02 Lepetit Spa

Also Published As

Publication number Publication date
IL172426A0 (en) 2006-04-10
CA2528938A1 (en) 2005-02-24
EP1648463A2 (en) 2006-04-26
BRPI0411364A (pt) 2006-07-25
JP2007500249A (ja) 2007-01-11
US20070010548A1 (en) 2007-01-11
KR20060070486A (ko) 2006-06-23
AU2004264834A1 (en) 2005-02-24
ZA200509961B (en) 2006-10-25
RU2006100484A (ru) 2006-06-10
CN1823067A (zh) 2006-08-23
WO2005016245A2 (en) 2005-02-24
WO2005016245A3 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
NO20060210L (no) Forbindelser med inhiberende aktivitet pa fosfatidylinositol-3-kinase og fremgangsmate for anvendelse av slike
ATE493131T1 (de) Chinazolin-4-one als inhibitoren der humanen phosphatidylinositol-3-kinase delta
MXPA02010618A (es) Inhibidores de fosfatidilinositol 3-quinasa delta.
WO2009064802A3 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
EP2612862A3 (en) Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
BRPI0513513A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
UY28130A1 (es) Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso.
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2006039691A3 (en) Morphine and morphine precursors
BRPI0514390A (pt) enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
WO2004101565A3 (en) Jnk inhibitors
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
WO2005002514A3 (en) Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof
ATE487485T1 (de) Verwendung von d-ribose zur behandlung von vorhofflimmern
AU2021322255A8 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
EP1597234A4 (en) NEW COMPOUNDS
EP1939203A3 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
IS2392B (is) Sítalópram til að meðhöndla hækkaðan blóðþrýsting
AU2003298244A1 (en) Method for inhibiting the replication of herpes viruses

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application